Cargando…
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
Autores principales: | Mohlin, Sofie, Hansson, Karin, Radke, Katarzyna, Martinez, Sonia, Blanco‐Aparicio, Carmen, Garcia‐Ruiz, Cristian, Welinder, Charlotte, Esfandyari, Javanshir, O'Neill, Michael, Pastor, Joaquin, von Stedingk, Kristoffer, Bexell, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949485/ https://www.ncbi.nlm.nih.gov/pubmed/31916402 http://dx.doi.org/10.15252/emmm.201911749 |
Ejemplares similares
-
Anti‐tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL‐302 in neuroblastoma
por: Mohlin, Sofie, et al.
Publicado: (2019) -
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
por: Kennedy, Sean P., et al.
Publicado: (2020) -
Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021) -
Multidimensional intratumour heterogeneity in neuroblastoma
por: von Stedingk, Kristoffer, et al.
Publicado: (2019) -
Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance
por: Mañas, Adriana, et al.
Publicado: (2022)